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Summary The crucial role of non-plasminogen dependent serine proteinases is tissue invasive and cytolytic
functions of Walker 256 cancer cells has been documented using a rat urinary bladder invasion and a 1251_
labelled fibroblast cytolysis assay. The invasive capacity of these cancer cells was abrogated by non toxic
concentrations of the serine proteinase inhibitors, diisopropylfluorophosphate and phenylmethylsulfonyl-
fluoride, but not by metallo or cysteine proteinase inhibitors. Although tumour cell collagenase activity and
plasminogen activator were demonstrated, these proteolytic enzymes were not essential in these in vitro assays.
These results suggest that different categories of proteinases play specific roles in the complicated process of
cancer invasion.
The capacity of malignant cells to invade
surrounding normal structures at both the primary
and metastatic organ sites is of central importance
in the dissemination of cancer (Poste & Fidler,
1980; Nicholson, 1979). Serine, cysteine and metallo-
proteinases have independently been implicated as
important enzymes in cancer invasion (Barrett,
1980). A dearth of experimental models has been a
limiting factor in understanding the role of specific
enzymes in cancer invasion. The purpose of this
report is to describe recently developed
experimental assay systems that we have used to
characterize the essential role of cancer cell
proteinases in tissue penetration and parenchymal
cell damage. Using pharmacologic agents, we have
identified the importance of each category of
proteinases in the highly invasive Walker 256 (W-
256) cancer cell line. Although both serine and
metalloproteinases were identified and often
enriched in W-256 tumour cell membranes, the
non-plasminogen dependent serine proteinase(s)
appeared to play the more crucial role in
parenchymal cell and tissue destructive effects of
cancer.
Materials and methods
RPMI 1640 was obtained from Flow Laboratories,
McLean, VA, N-a-P-tosyl-L-lysine chloromethyl
ketone (TLCK), diisopropylfluorophosphate
(DFP), soybean trypsin inhibitor (SBTI), N-ethyl-
maleimide (NEM), Trypsin-TPCK, phenylmethane-
sulfonylfluoride (PMSF), and 1, 10 phenanthroline
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were obtained from Sigma Chemical Co., St. Louis,
Mo, USA. s-Aminocaproic acid was obtained from
Lederle Laboratories, Pearl River, NY, USA.
Leupeptin was kindly supplied by Dr. Umezawa.
l25I-5' iodo-2 deoxyuridine (1251-UdR) was
obtained from Amersham, Arlington Heights, IL,
USA. Ethylenediaminetetraacetic acid (EDTA) was
obtained from BDH Chemicals Ltd., Poole, UK.
Urokinase was obtained from Calbiochem, La
Jolla, CA. Peptide P Collagenase substrate from
United States Biochemical Corp., San Diego, CA,
and Dioxane from Fisher Co., Fairlawn, NJ, USA.
Animals and cells
Male Wistar rats were used throughout. Walker
256 (W-256) carcinosarcoma, obtained from Arthur
D. Little Co., Boston, MA, were serially trans-
planted as a highly invasive ascitic tumour and
were isolated free of contaminating cells on Ficoll-
Hypaque as previously described (Zucker & Lysik,
1977; DiStefano et al., 1982). L-929 fibroblasts,
obtained from Flow Laboratories, were propagated
in vitro in RPMI-1640+10% heat-inactivated foetal
calf serum. All cells were washed three times in
RPMI-1640 to remove all serum components prior
to study.
Radiolabelling ofcells
L-929 fibroblasts (106ml-1) were radiolabelled in
vitro with 0.5juCi 125I-5' iodo-2 deoxyuridine for
24h. Fibroblasts were then collected by trypsini-
zation, washed thoroughly, and used as a single cell
suspension. W-256 cancer cells were radiolabelled in
vivo by injecting 1O0Ci of 125I-UdR i.p. into ascites-
bearing rats 24h prior to sacrifice (day 6 after
tumour transplantation) and then harvested and
prepared for assays as described above. This radio-
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labelling procedure did not alter the invasive or
cytolytic capacity of W-256 cells.
Tumour-inducedfibroblast lysis assay
To provide a better model of cancer cell:normal
cell interactions occuring during tumour cell
invasion of most parenchymal organs, we have now
modified the tumour-induced erythroid cytolysis
assay (DiStefano et al., 1982) to quantify the
cytolytic effect of cancer cells on fibroblast target
cells. '25I-UdR labelled fibroblasts (5 x 106 cells)
were mixed with 5 x 106 unlabelled W-256 cells
suspended in 1 ml of RPMI-1640 and the mixed cell
cultures were incubated at 37°C for 24, 48 and 72h.
Cultures were then centrifuged at 770g for 10min
and the supernate and cell pellet were separated
and radioactivity was measured in a gamma
counter. Fibroblast lysis (Release Index) was
calculated by comparing 125I in the supernate to
total 1251 (supernate and pellet). Drug treatment of
W-256 cells was done as previously described with
30min pre-incubation with non-toxic concentrations
of agents prior to concurrent incubation of drug-
treated tumour cells with fibroblast target cells
during the 1-3 day assays (DiStefano et al., 1982).
Drug-induced inhibition of cytolysis was calculated
using the mean of the release index (RI).
% of Inhibition of Cytolysis=
[RI target cells+drug-treated effector cells)-
RI (drug-treated target cells)] 1-
[RI (target cells+control effector cells)-
RI (control target cells)]
x 100
Effect ofpharmacologic agents on cancer cell and
fibroblast viability
The viability of drug-treated cancer cells and fibro-
blasts was ascertained by measuring tumour colony
formation in methyl cellulose (>8 cells per colony)
after 3 days of cell incubation in the presence of
drugs (Zucker et al., 1980), and the 3 day
incorporation of 3H-thymidine and '4C-leucine into
tumour cell and fibroblast DNA and protein,
respectively, as previously described (DiStefano et
al., 1979). Drug concentrations resulting in <80%
cell viability as determined by trypan blue dye
exclusion were excluded from further study.
Bladder invasion assay
In our modification of the urinary bladder invasion
assay, described originally by Hart (1979), male rats
were killed and the peritoneal cavity was exposed
using asceptic technique. The urinary bladder was
emptied of its content, and the ureters were tied off.
A 0.5ml suspension of '25I-UdR labelled or
unlabelled W-256 or L929 cells (2x 106m -1) was
injected into the urinary bladder by retrograde flow
through the urethra. A urethral ligature was then
tightened. The bladder was then excised, and placed
either upright in 10 x 75mm friction cap tubes
containing 8ml of NCTC-135 for radioactive
counting or in 35mm plastic Petri dishes containing
a preformed base of 3% methylcellulose in NCTC-
135 for colony counting. After 48h of incubation at
37°C in 5% CO2 and 95% air, the bladders were
removed from the tubes and radioactivity of the
external fluid bathing the bladder and the intact
bladder were separately measured in a gamma
counter. The overall integrity of the bladder wall
was checked by injecting india ink in the bladder
lumen (Poste et al., 1980). In colony experiments
the methyl cellulose embedded bladders were
removed after 48h of incubation and tumour
colonies forming in the semisolid media were
counted as we have previously described (Zucker et
al., 1980). In various experiments, 125I-labelled or
non-labelled W-256 cells were pre-treated with
pharmocologic agents (DiStefano et al., 1982) for
30min before injecting the tumour cells into the
bladder. Significant differences between groups were
calculated by the Student's "t" test.
Assay ofplasminogen activator
Plasminogen-dependent fibrinolytic activity of W-
256 cells and the effects of proteinase inhibitors on
cancer cell PA was determined using 3H-fibrinogen
(90pg per plate) clotted with 5% FCS with the
addition of human plasminogen (20gml-1) as
previously described (Barrett et al., 1977). W-256
cell homogenates and cell membranes (1 pg samples)
were added, with or without pharmacologic agents,
and after 18h of incubation at 37°C, the release of
3H by tumour cell fractions was compared to
maximum release produced by an excess of
urokinase (1 ploug unit=100%).
Assays ofcollagen degradation
The synthetic peptide P substrate, (2,4
dinitrophenyl) DNP-Pro-Gln-Gly-Ile-Ala-Gly-Gln-
D-Arg-OH was employed to quantitatively assay
tumour cell collagenase-like activity (Masui et al.,
1977: Grant & Eisen, 1980). This peptide (P)
possesses a sequence identical with that in the
region of the vertebrate collagenase sensitive Gly-
Ile bond in the al chain of Type I collagen except
that the amino terminus is blocked by a DNP
group and the carboxyl terminal residue is the
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residue. As described by Masui et al. (1977)
5 x 10-4 M DNP-Peptide P was dissolved in 0.05M
NaCl, 5mMCaCl2 buffer, pH7.8, containing 0.02%
albumin and incubated at 37°C with an equal
volume of tumour cell sample or bacterial
collagenase. After 18h, the the enzymatic reaction
was stopped by adding IM HCI. The released
DNP-peptide fragments were then extracted into
the organic layer with ethyl acetate-n-butanol and
the degree of hydrolysis was determined by
measurement of absorbance.
Latent collagenase assay
The degradation of collagen was measured using
acid soluble rat skin type I collagen labelled in vitro
with 3H-formaldehyde using a modification of the
technique of Bhatnagar & Decker (1981). In brief,
70pl of tumour cell fractions or standards were
activated with 25pg trypsin-TPCK for 15min and
then inactivated with 125Mg of soubean trypsin
inhibitor. The individual samples, reagent blanks,
trypsin-SBTI and collagenase controls were then
incubated with lOg of (3H-methyl) collagen and
maintained in solution rather than in fibrillar form
at 27°C for 36h with gentle agitation. The reaction
was stopped with 1,10 phenanthroline, and the
undigested collagen was precipitated by the
addition of dioxane (50% final concentration). The
reaction mixture was then passed through 1.2gm
pore filters (Acrodisc-Gelman Co., Ann Arbor, MI)
and an aliquot of the filtrate containing the
collagen degradation products was added to
Hydrofluor (National Diagnostics, Somerville, New
Jersey) and counted in a liquid scintillation
spectrometer. In these experiments, the spontaneous
breakdown of 3H-collagen in 36h amounted to
< 1% and rose to 3% after trypsin-SBTI treatment.
Activity was expressed as percent degradation of
lOug ofcollagenmg- of tumour protein.
Results
L-929 fibroblasts had a low spontaneous RI of 2.2%
during 72h of incubation, hence serving well as
target cells to monitor the cytolytic capacity of
tumour cells. The data in Table I indicate that W-
256 cancer-induced fibroblast lysis began at 48h
and increased by 72h. Concurrent treatment of
mixed cell cultures with DFP and PMSF (broad
Table I The cytolytic effect of W-256 cancer cells on L929 rat fibroblasts
Additions to Time 125I-Fibroblast release
L929 Fibroblasts (h) (%)
W-256 cells 24 1.33a+0.14
W-256 cells 48 9.51 +0.77
Buffer (no cells) 72 2.22+0.14
W-256 cells 72 15.04+ 1.19
W-256 cells+DFP 72 3.58+0.35 (-93.54+4.15)a,b
W-256+PMSF 72 8.73+ 1.28 (-42.37+ 12.31)b
W-256+TLCK 72 9.14+0.65 (-41.23+10.85)b
W-256+Cu + 72 3.54+0.42 (-84.46+6.21)b
W-256+Emetine 72 7.04+0.38 (-53.59+11.94)b
W-256+
1, 10 Phenanthroline 72 15.71 + 1.62 (0)
EACA 72 15.44+1.06 (0)
aMean+s.d.
bp<0.001 as compared to controls.
Numbers in parenthesis denote % stimulation (+) or inhibition (-) by
concurrent treatment ofmixed cell cultures with the various agents.
125I-UdR labelled L929 fibroblasts (5 x 106) were mixed with 5 x 106 W-
256 cancer cells suspended in 1 ml of RPMI-1640 (without foetal calf serum)
and incubated at 37°C for 1, 2 and 3 days. The cultures were terminated by
centrifugation and the radioactivity in the supernate and pellet were
measured. Fibroblast lysis (Release Index) was calculated by comparing 125I
in the supernate to total 125I (supernate and pellet). All samples were run in
triplicate and reported as the mean±s.d. The 72h experiment included a
concurrent incubation of W-256 cancer cells with the proteinase inhibitors
DFP (10-3M), PMSF (2x 10-4M), EACA (2x 10-3M), Cu+I (10-3),
1,10 phenanthroline (10-3 M) and the inhibitor of protein synthesis,
emetine (10-4M). These drugs alone did not increase the baseline 125I1
Fibroblast release.
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spectrum serine proteinase inhibitors), TLCK
(active site trypsin-like inhibitor), Cu+ + (non-
specific inhibitor of elastase-like serine and cysteine
proteinases) or emetine (an inhibitor of protein
synthesis) produced significant inhibition of cancer-
induced fibroblast lysis (DiStefano et al., 1982;
Quigley, 1979; Strauli et al., 1977, Stevens et al.,
1983). s-amino caproic acid (an inhibitor of
plasmin), and 1,10 phenanthroline (metalloprotein-
ase inhibitor), had no significant effect on fibroblast
lysis. Walker 256 cells incubated with 10- MDFP,
5 x 10-4MTLCK, and 2 x 104 MPMSF did not
lead to inhibition of tumour colony forming
efficiency which remained at 14% on day 3.
Copper (10-3), 1,10 phenanthroline (10-3), and
emetine (10-3M) reduced tumour colony forming
efficiency to 1%, 2%, and 1%, respectively. As
previously described with 1 day drug co-incubations
(DiStefano et al., 1982), DFP, PMSF, and TLCK
produced 8, 17, and 27% inhibition of DNA and
protein synthesis during 3 days of incubation, while
copper, 1,10 phenanthroline, and emetine inhibited
W-256 cell DNA and protein synthesis by >90%.
L-929 fibroblast and DNA and protein synthesis
over 3 days were minimally inhibited by DFP,
PMSF, and TLCK and were markedly inhibited
(>90%) by 1,10 phenanthroline and copper. The
necessity of tumour-cell:target cell contact is
demonstrated by the following cell separation
experiment. Separation of W-256 cells from 125i-
fibroblasts by a Millipore filter as we have
previously described resulted in 98% ablation of
fibroblast lysis (DiStefano et al., 1982). Likewise the
supernatant fluid collected from 1-3 day cultures of
W-256 cells did not induce the lysis of 1251-fibro-
blasts during a 3 day incubation.
Based on our previous demonstration of serine
proteinase activity in W-256 cancer cell membranes
and the cytolytic activity of cancer cell membranes
for erythroid cells (DiStefano et al., 1982), we
evaluated the effect of W-256 cell membranes on
125'-labelled fibroblasts. Walker 256 cell membrane
enriched fractions (96% pure) were isolated and
characterized as previously described (DiStefano et
al., 1982). As noted in Table II, the induction of
fibroblast lysis by tumour cell membranes as
compared to intact W-256 cancer cells occurred
earlier (24h) and to a greater extent. By comparing
the protein content of cell membranes to intact W-
256 cells, we demonstrated a 110-fold enrichment in
specific activity for cancer membrane-induced fibro-
blast lysis. Pretreatment of W-256 membranes with
DFP or PMSF results in significant inhibition of
cancer cell membrane-induced fibroblast lysis (Table
II). From these experiments and our previous
characterization of W-256 enzymes, we conlude that
W-256 cancer cell serine proteinases, with trypsin-
like specificity which are localized to the cell
membrane are responsible for the destruction of
fibroblasts in vitro.
A urinary bladder penetration assay was used to
evaluate the invasive potential of malignant cells in
an intact organ. Tumour cell penetration through
the bladder wall requires a breach of the basement
Table II The cytolytic effect of W-256 cancer cell membranes on '25I-labelled L929
fibroblasts
Additions to 7ime
L929fibroblasts (h) '25I-Fibroblast release (%)
Buffer 72 2.02+0.36a
Intact W-256 cells 24 2.81 +0.51
W-256 cell membranes 24 10.03+0.79b
Intact W-256 cells 48 8.91 +0.30b
W-256 cell membranes 48 24.21+0.36b
Intact W-256 cells 72 17.57+1.88b
W-256 cell membranes 72 65.99+6.49b
W-256 cell membranes+DFP 72 44.66+4.53b (-33.9+9.7c)
W-256 cell membranes+PMSF 72 39.73+0.65b (-41.3±6.2)
aMean+s.d.
bp<O.001 as compared to controls.
CSee footnote to Table I.
Walker 256 cell membranes were prepared by hypotonic lysis followed by sucrose density
gradient centrifugation and characterized by marker enzyme analysis and electron
microscopy as previously described (DiStefano et al., 1982). Walker 256 cell membranes
(100igml 1) or intact W-256 cells were incubated with 125I-labelled L929 fibroblasts
(5 x 106ml-l) for 1, 2 or 3 days and fibroblast lysis was measured as noted in Table I. The
72h experiment included a concurrent incubation of W-256 cell membranes with DFP
(I0-3 M) or PMSF (2 x 10- M). These enzyme inhibitors alone did not affect the baseline
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Table III The effect of proteinase inhibitors on the invasiveness of Walker 256 cancer
cells in urinary bladder organ cultures from rats
Concentration
Pharmacologic agents (M) Invasion index (%)
None (control) 54.9+ 1.8a
DFP 10-3 17.3+4.4b (-68.4+8.0d)
TLCK 5 x 10' 33.7+8.3b (-38.6+ 15.2)
PMSF 2 x 10'4 37.9+7.9c (-30.9+ 14.5)
Leupeptin 10- 3 55.3+11.7 (+0.7+21.5)
Copper 10-3 48.4+ 12.2 (-11.8+22.4)
1,10 Phenanthroline 10-3 69.1+8.4 (+25.8+15.8)
Emetine 10-4 42.1 +2.9 (-23.3+ 5.8)
EACA 2 x 10-3 53.7+0.4 (-2.1 +3.2)
aMean+s.d.
bp<0.001 as compared to controls.
cP<0.05 as compared to controls.
dSee footnote to Table I.
Isolated bladders from male Wistar rats were given injections of 106 viable 125I-UdR
labelled W-256 cancer cells that had been preincubated for 30min with non-toxic
concentrations of 7 different proteinase inhibitors and emetine. Organ cultures were
incubated for 2 days at 37°C after which the bladders were removed from the tubes and
radioactivity of the external fluid bathing the bladder (representing cells penetrating the
full thickness of the organ) and the intact bladder were separately measured in a gamma
counter. 1251 radioactivity associated with the tumour cells which had penetrated through
the bladder into the external fluid was expressed as a percentage of the initial total
cellular radioactivity (Invasion Index). The results are compiled from 10 different
experiments in which buffer treated W-256 cells were compared to 2-3 different
proteinase-inhibitor treated tumour cells. The number of bladders tested per treatment
group varied between 6 and 20.
membrane, fibrous connective tissue stroma and
muscle components (Poste et al., 1980). In the initial
experiments we demonstrated that 40-60% of 125-
labelled W-256 cells penetrated the rat urinary
bladder during a 48h incubation. By contrast, 2%
of alcohol-treated W-256 cells and 8% of 125I-UdR-
labelled L929 fibroblasts (a non-invasive cell line)
had penetrated the bladder in a 48h period thus
supporting the resistance of the urinary bladder to
penetration by dead tumour cells or non malignant
cells. Pretreatment of W-256 cancer cells with non-
toxic concentrations of DFP, PMSF or TLCK
inhibited bladder wall penetration by 68%, 31% and
39%, respectively (Table III). s-amino caproic acid
(EACA), Cu+, leupeptin, (an arginine containing
peptide analogue inhibitor of serine and cysteine
proteinases, especially cathepsin B), and 1, 10
phenanthroline, did not affect W-256 invasion of
the bladder. Short-term incubation with emetine
inhibited bladder invasion by 23%.
To ascertain whether the passage of 1251 through
the urinary bladder represented intact cancer cells
with proliferative capacity of 1251 release from
damaged cancer cells, we examined the colony
forming ability in agar of W-256 cells that had
penetrated through the urinary bladder. Two days
after instilling 106 cancer cells into the bladder, 406
+31 W-256 colonies were noted in the surrounding
semisolid media. Pretreatment of the W-256 cells
with DFP resulted in 74+19 colonies per plate
which indicated 82% inhibition of invasion. As
noted above, DFP alone did not inhibit W-256
colony formation. Based on these pharmacologic
experiments, we conclude that W-256 cancer cell
serine proteinases are essential for cancer invasion
through a urinary bladder.
Plasminogen-dependent fibrinolytic activity of W-
256 cancer cells and the effect of various proteinase
inhibitors on cancer cell PA was determined in an
18h assay using 3H-fibrinogen and human
plasminogen (Table IV). As anticipated, W-256 cell
membranes and whole cell homogenates were rich
in PA activity, which could be abrogated by pre-
treatment with EACA, DFP, SBTI (soybean protein
inhibitor of trypsin-like enzymes), and TLCK. Since
EACA, a plasmin antagonist was able to completely
inhibit fibrinolysis in this experiment, without
affecting bladder invasion (Table III) or fibroblast
target lysis (Table I), it appears that W-256 cancer
invasion is unrelated to plasminogen activation. In
contrast, the more general serine proteinase
inhibitors (DFP, PMSF) were able to inhibit both
the fibrinolytic and invasive aspects of W-256
cancer cells.228 S. ZUCKER et al.
Table IV Plasminogen-dependent fibrinolytic activity of Walker 256
cancer cells and the drug-inhibitory profile
3H-Fibrin release % Inhibition
Sample % per gg sample offibrinolysis
Buffer 0
Urokinase (lPloug unit) 100
W-256 homogenate 38.8
W-256 cell membranes 46.1
W-256 membrane+DFP 9.1 80
W-256 membrane+TLCK 9.3 80
W-256 membrane+EACA 0 100
W-256 membrane+SBTI 0 100
3H-fibrin was clotted on petri dishes using foetal calf serum with the
addition of human plasminogen. Walker 256 cell homogenates and cell
membranes (1 Mg samples) were then added. After 18h of incubation at
37°C the release of solubilized fibrinopeptides was measured. The release
of 3H by tumour cell fractions was compared to maximum release
produced by urokinase (1 ploug unit= 100%). The serine protease
inhibitors, DFP, TLCK, EACA at concentrations shown in Table I and
SBTI (2 x 10-5M) were preincubated with W-256 cell membranes for
30min prior to performing the standard fibrinolytic assay.
Table V Collagenase-like activity of W-256 cancer cells as measured by the hydrolysis of the synthetic
substrate for collagenase DNP-Pro-Gln-Ile-Ala-Gly-Gln-D-Arg-OH (Peptide P)
Concentration Rate ofhydrolysis Specific activity
Sample (Mg protein/assay) (OD365118h) (OD/mg)
Solublization buffer 0 0.007+0.003
W-256 whole cell homogenate 58.8 0.249+0.025 0.0042
W-256 cell membranes 60.5 0.275+0.013 0.0045
Bacterial collagenase 400 (60U) 0.234+0.009 0.00058
Trypsin 100 0 0
5 x 10-4M DNP-Peptide P was dissolved in buffer and incubated with an equal volume of tumour cell
homogenate, cell membrane (Triton X-100 solubilized), bacterial collagenase, or trypsin. After 18h the enzyme
reaction was stopped and the released DNP-Peptide fragments were determined by measuring the absorbance
(OD 365) in the organic layer.
Collagenolytic activity of W-256 cells was
assessed using two different approaches. Table V
shows that W-256 cell homogenates and isolated
cell membranes possess considerable collagenase-
like activity, as monitored using the synthetic
substrate, Peptide P, without enzyme enrichment in
the cell membrane fraction as assessed by specific
activity. To determine the category of enzyme(s)
mediating this collagenase-like activity, we
preincubated W-256 cell membranes with inhibitors
of the metallo, serine and cysteine proteinases
(Table VI). The metalloenzyme inhibitors 1,10
phenanthroline, EDTA and dithiothreitol effectively
inhibited the hydrolysis of Peptide P (100%, 100%
and 70% respectively). The serine proteinase (DFP,
PMSF) and cysteine proteinase inhibitors (N-ethyl-
maleimide, leupeptin) had no significant effect of
Peptide P hydrolysis. Since peptidases without
collagenase activity can also cleave Peptide P (Gray
& Saneli, 1982), a specific assay for collagenase was
performed using soluble Type I 3H-collagen.
Walker 256 cells were rich in latent collagenase
activity producing 15.9% degradation of substrate
mg-' protein with considerable enrichment (6.2 x)
in the plasma membrane fraction (99% degration
mg-' protein). The metalloenzyme inhibitors,
EDTA and 1,10 phenanthroline, produced >90%
inhibition of W-256 cell collagenolytic activity.ROLE FOR PROTEINASES IN CANCER INVASION 229
Table VI Requirement for metalloenzyme activity in W-256 cell membrane induced
hydrolysis of Peptide P
Rate ofhydrolysis
Sample Pharmacologic agents (OD/18h) (%)
Walker 256 membrane None 0.126 (-)a
Walker 256 membrane DFP (10-3M) 0.120 (-5)
Walker 256 membrane 1,10 phenanthroline (10-2 M) 0 (-100)
Walker 256 membrane N-ethyl maleimide (10-3 M) 0.123 (-2)
Walker 256 membrane PMSF (2 x 10-4M) 0.128 (+2)
Walker 256 membrane EDTA 0 (-100)
Walker 256 membrane Leupeptin (10-3 M) 0.125 (-1)
Walker 256 membrane DTT (10-3 M) 0.039 (-69)
aSee footnote to Table I.
The effect of different protease inhibitors on the rate of hydrolysis of Peptide P after an
18h incubation with W-256 cell membranes (66pg) was measured as described in Table
V. Pharmacologic agents were preincubated with the tumour cell membranes for 10min
before adding the mixture to Peptide P.
Table VII Latent collagenase activity of W-256 cancer cell homogenate and plasma membranes
Pharmacologic 3H-Collagen degradation % Inhibition of
Sample agent (% substrate mg-' protein) collagenolysis
W-256 whole cell
homogenate (WCH) None 15.9
W-256 whole cell
homogenate (WCH) EDTA 0.5 97
W-256 whole cell
homogenate (WCH) 1,10 phenanthroline 8.3 48
W-256 plasma
membranes None 99.0
W-256 plasma
membranes EDTA 9.1 90
W-256 whole cell
membranes 1,10 phenanthroline 11.7 88
Tumour cell fractions were activated with trypsin-TPCK, inactivated with SBTI and then incubated at 27°C for
36h with 10pg (3H-methyl) Type I collagen. Undigested collagen was then precipitated by the addition of dioxane
and radioactivity in the filtrate containing collagen degradation products was measured. In the absence of trypsin
activation, W-256 cell homogenate lacked measurable amounts ofcollagenase activity.
Minimal collagenase activity was noted in W-256
cell fractions without prior trypsin activation (Table
VII).
Discussion
The direct interaction between cancer cells and
normal cells during the invasive process has been a
difficult problem for experimental evaluation
(Mareel, 1981). Taking advantage of the enhanced
susceptibility of erythroblasts and red blood cells to
experimental lysis, Zucker & Lysik (1977)
introduced the tumour-induced erythroid cytolysis
assay (TIEC) to assess the capacity of cancer cells
to destroy normal host cells. All 13 cancer cell lines
tested to date have been capable of lysing normal
59Fe-labelled bone marrow and red blood cells
(Lysik et al., 1979: DiStefano et al., 1983b; Stevens
et al., 1983). Using highly invasive W-256 rat cancer
cells, DiStefano et al. (1983b) were able to localize
and identify serine proteinases in the cancer cell
membrane that were responsible for the lysis of
normal erythroid cells. One of these W-256
membrane enzymes, Memsin, has been purified and
characterized as a highly active trypsin-like serine
proteinase (LaBombardi et al., 1983).
In this report we have shown that intact W-256
cancer cells are able to lyse 125I-UdR labelled
fibroblasts by a cell contact requiring phenomenon.
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represents loss. of DNA from the dying cell. Isolated
cancer cell membranes were highly enriched in
cytolytic function. Based on the inhibition of
tumour-induced fibroblast lysis by non-toxic con-
centrations of DFP and PMSF, we conclude that
W-256 cancer cell serine proteinases with trypsin-
like specificity and localization in the cell membrane
are responsible for the destruction of fibroblasts in
vitro. The absence of fibroblast lysis when tumour
cells were physically separated from "25I-labelled
fibroblasts in culture and when fibroblasts were
cultured in tumour-conditioned media serves to
exclude the possibilities that nutritional deprivation
or cancer cell secretion of toxic substances are
causative factors in fibroblast lysis. Of interest, the
inhibitory effect of 1,10 phenanthroline on tumour
colony formation, DNA and protein synthesis and
on fibroblast DNA and protein synthesis did not
lead to diminished tumour-induced fibroblast lysis.
This is consistent with our previous studies of W-
256 induced erythroblast lysis, where we
demonstrated that agents which primarily inhibit
DNA synthesis had no significant effect on tumour-
induced RBC lysis (DiStefano et al., 1979). By
contrast, the cytolysis inhibitory effect of emetine is
probably due to the profound inhibition of tumour
protein synthesis, presumably the cytolytic protein-
ases. Finally, we cannot exclude the possibility that
the inhibition of fibroblast lysis produced by copper
may be due to a toxic effect on tumour cells. A
propos of our work, Sakiyama et al. (1984) have
shown that metastatic cancer cells can solubilize
and phagocytose fixed cells by a plasminogen-
dependent cell contact requiring phenonemon.
Cancer cell attack of fixed cells was abrogated by
inhibitors of trypsin-like proteinases, suggesting that
the degredation of target cell proteins is a serine
proteinase requiring phenomenon.
To evaluate invasiveness through tissue
components of an intact organ, we examined the
penetration by cancer cells of an isolated rat
urinary bladder over a 2 day period. In the reports
by Hart (1979) and Poste et al. (1980) using a
mouse urinary bladder and variant melanoma cell
lines, a 7 day period was required for tumour cell
penetration of the bladder. By contrast, rat W-256
cancer cells were highly invasive of a rat urinary
bladder in a 2 day period. Using different categories
of proteinase inhibitors we showed that bladder
invasion required non plasminogen dependent
serine proteinases, which is consistent with our data
in the fibroblast lysis assay. Explanations for the
effects of proteinase inhibitors on cancer cells other
than a direct action on invasive enzymes cannot be
excluded. Pharmacologic inhibition of cancer cell
motility or aspects of invasion other than tissue
destruction need to be considered.
In these experimients we confirmed that W-256
cancer cells possess metalloenzymes with type I
collagenolytic activity (Wolf & Wirl, 1982).
However, based on the ineffectiveness of metallo-
enzyme inhibitors in altering urinary bladder
invasion or normal fibroblast cytolysis, we conclude
that metalloenzymes are not crucial in these assays.
The role of collagenases in W-256 cancer invasion
in vivo cannot be directly extrapolated from the
current study, especially in organ sites rich in type
IV basement membrane. The metalloenzyme,
collagenase, has been well characterized in many
cancer cell lines. Liotta et al. (1980, 1981)
demonstrated a positive correlation between cancer
cell collagenase with specificity for type IV collagen,
a component of vessel wall basement membrane,
and the invasive and metastatic capacity of various
cancer cells. While we have not demonstrated a
requirement for metalloproteinases in W-256 cancer
cell-induced lysis of fibroblasts or erythroid cells, in
other studies employing murine B16 melanoma cell
lines, cancer-induced target cell lysis required
metalloproteinases as evidenced by an inhibition of
cytolysis elicited by metal chelators (DiStefano et
al., 1983b).
Although plasminogen activator was identified in
W-256 cancer cells and membranes using a 3H-
fibrinogen substrate with added plasminogen, the
generation of plasmin in the fibroblast cytolysis
assay did not appear to be a critical factor as
evidenced by a lack of requirement for exogenous
plasminogen and the absence of an inhibitory effect
of EACA, a plasmin inhibitor, in target cell
destruction.
The importance of different categories of
proteolytic enzymes in cancer invasion and meta-
stasis has been repeatedly stressed. Bossman et al.
(1973) initially reported a positive correlation
between the metastatic ability of B16 melanoma
variants and an increase in tumour cell trypsin and
cathepsin-like serine proteinases. Numerous
correlations between cancer cell metastatic
characteristics and plasminogen activator have been
reported (see review by Duffy & O'Grady, 1984).
Using antibodies against plasminogen activator in a
chick embryo experimental model of metastasis,
Ossowski & Reich (1983) demonstrated that
plasminogen activator was crucial for metastasis by
selected cells.
High levels of lysosomal and cell membrane
cysteine proteinases (Cathepsin B) have been found
in cancer cell lines with enhanced metastatic
capability (Recklies et al., 1982; Sloane et al., 1981;
Pietra & Roberts, 1981). We have found that
although W-256 cancer cells have cysteine
proteinase activity (data not shown), the inhibition
of this category of proteinases by leupeptin had noROLE FOR PROTEINASES IN CANCER INVASION 231
effect on the in vitro invasion assays that we
employed here.
These studies reemphasize the extreme biological
variability of cancer in that an individual cancer cell
may contain several types of proteinases which may
or may not correlate with metastatic potential.
Recently Lowe & Isaacs (1984) reported that pros-
tatic cancer cell lines of low and high metastatic
potential possess a large array of proteinases with
no single enzyme activity correlating with
metastatic potential.
To date, the goal of most investigations has been
to determine a correlation between a category of
cancer proteins (hydrolytic enzymes, surface glyco-
proteins, etc.) and metastatic or invasive potential
of cancer cell lines. In this study we have shown
that pharmacologic agents can be used to better
characterize the role of specific proteinases in
experimental models that examine various factors
involved in cancer invasion and normal cell
destruction in vitro. The potential use of proteinase
inhibitors in the treatment of cancer has not yet
been systematically explored (Nelles & Schnebli,
1982). Our report suggests that the selection of
enzyme inhibitors for future in vivo testing should
be based on in vitro assays using the specific cancer
cell line to be evaluated.
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